Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients

Desoky, Ehab S El; Sabarinath, Sreedharan Nair; Hamdi, M. M.; Bewernitz, Michael; Derendorf, Hartmut

doi:10.1111/j.1365-2710.2011.01296.x

Cited by 8 publications

(3 citation statements)

References 29 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Generally, DRE subjects received higher doses of CBZ than seizure free subjects and demonstrated an approximately 4% higher CL/F plasma as compared to their counterparts. Nevertheless, this difference was not significant, a result comparable to an Egyptian study . These observations support the fact that PWE with harder to control seizure does require significantly higher amount of CBZ in order to attain therapeutic concentrations, and it may be related to the lower free fraction of CBZ.…”

Section: Discussionsupporting

confidence: 74%

“…The population estimate of CL/F plasma of approximately 5.9 L/h concurred with those found in previous studies. As majority (72%) of this population was on polytherapy, CL/F plasma estimated are similar to the other polytherapy populations . Interestingly, CL/F dbs derived using similar PPK approach resulted in similar model specifications and identical parameter estimate with CL/F plasma .…”

Section: Discussionmentioning

confidence: 56%

See 1 more Smart Citation

Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: The clinical implication

Kong

Lim

Chan

et al. 2013

The Journal of Clinical Pharmacology

View full text Add to dashboard Cite

To establish using dried blood spot (DBS) as a surrogate to plasma for therapeutic drug monitoring (TDM) of carbamazepine (CBZ), we compared the population pharmacokinetic (PPK) estimates from concurrent DBS and plasma levels. The dose-concentration relationship, estimated parameter and variability were determined. A total of 98 observations from 97 people with epilepsy (PWE) were included in this study. Data was split into 3:1 ratio for the respective index group and validation group. Non-linear mixed effects regression with one compartment, first order absorption and elimination model was utilized. Covariates were screened for inclusion into final model via forward stepwise addition and backward elimination method. Predictive performances of the final models were assessed for bias and precision. The typical clearance for CBZ was estimated to be 5.85 and 5.68 L/h from plasma and DBS concentrations, respectively. The final models for clearance estimates obtained from plasma concentrations (Cplasma ) included total daily CBZ dose per unit weight (DD) and sex while from DBS concentrations (Cdbs ) included only DD. The final models were both precise and non-bias. The developed PPK models had comparable estimates, errors and predictive performances. Our findings suggest that Cplasma and Cdbs could be used interchangeably for pharmacokinetic studies of CBZ.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 56%

Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: The clinical implication

Kong

Lim

Chan

et al. 2013

The Journal of Clinical Pharmacology

View full text Add to dashboard Cite

show abstract

“…De cette façon, le STP a aidé le clinicien au diagnostic de toxicité surtout chez les patients dont le statut était difficile à évaluer cliniquement comme les jeunes enfants et les sujets souffrant de troubles mentaux [ 32 ]. Une fois la dose est ajustée, le clinicien pourra connaître la concentration plasmatique efficace propre au patient et constituer une référence individuelle qui pourra l'aider à mieux gérer les prises de décisions face à une modification de l´état clinique se produisant au fil du temps [ 33 – 37 ].…”

Section: Discussionunclassified

Suivi thérapeutique pharmacologique de trois médicaments antiépileptiques: retour sur vingt années d’expérience

Serragui¹,

Zalagh²,

Tanani³

et al. 2016

Pan Afr Med J

View full text Add to dashboard Cite

IntroductionLe suivi thérapeutique pharmacologique (STP) des médicaments antiépileptiques (MAE) est un outil très utilisé dans la gestion de l'épilepsie. Au Maroc, ce dosage est réalisé au Centre Anti Poison et de Pharmacovigilance du Maroc (CAPM) depuis Avril 1995.MéthodesIl s'agit d'une étude rétrospective s'étalant sur 20 ans. Elle concerne le STP du Phénobarbital (PB), de la Carbamazépine (CBZ) et de l'Acide Valproique (AVP).RésultatsLe STP des 3 MAE représentaient 58,85% de l'ensemble des demandes de STP reçue par le CAPM. Le dosage du PB était classé en première position suivi par celui de la CBZ et enfin par l'AVP. La faible demande de STP au Maroc pouvait être expliquée par le faible nombre de neurologues auquel s'ajoutaient des facteurs sociaux. Grâce à son prix très accessible par les patients, le PB est le MAE le plus prescrit dans notre pays expliquant ainsi la demande élevée de son dosage. Quant aux motifs de STP des 3 MAE, ils étaient essentiellement liés à l'âge, à l'apparition d'effets indésirables, à l'association de MAE ou dans le cas de vérification de l'observance des malades.ConclusionDes efforts sont à fournir pour promouvoir l'intérêt du STP des MAE dans la prise en charge de l'épilepsie au Maroc.

show abstract

CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy

Djordjević

Milovanović

Radovanovic

et al. 2016

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients

Abstract: The POP PK model we have developed for CBZ shows good predictive performance in Egyptian adult and pediatric patients with epilepsy. Another PK study to better define the effect of different covariates would improve on the model for dosage individualization.

Cited by 8 publications

References 29 publications

Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: The clinical implication

Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: The clinical implication

Suivi thérapeutique pharmacologique de trois médicaments antiépileptiques: retour sur vingt années d’expérience

CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy

Contact Info

Product

Resources

About